PDSB241220P7500
- 0.00
- 0.000.00%
PDS Biotechnology Newsroom
PDS Biotechnology Analyst Ratings
B.Riley Financial Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Cuts Target Price to $7
Strategic Changes in PDS Biotechnology's Clinical Trial Design Position Stock as Attractive Buy Opportunity
Earnings Preview: PDSB to Report Financial Results on November 14
Noble Financial Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $17
PDS Biotechnology | 10-Q: Q3 2024 Earnings Report
12 Health Care Stocks Moving In Thursday's Pre-Market Session
PDS Biotechnology Price Target Lowered to $4.50 From $7 at Alliance Global Partners
PDS Biotechnology Shares Down 18% After Phase 3 Trial Modifications
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript Summary
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
PDS Biotechnology Reports Q3 EPS (29c), Consensus (28c)
PDS Biotechnology | 8-K: PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
Express News | PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
Express News | PDS Biotechnology Q3 Net Income USD -10.7 Million
Press Release: PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
Express News | PDS Biotechnology Q3 EPS USD -0.29 Vs. IBES Estimate USD -0.28
Earnings Scheduled For November 14, 2024
Here's the Major Earnings Before the Open Tomorrow
Uncovering Potential: PDS Biotechnology's Earnings Preview